MELD uses the patient's values for serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time to predict survival. It is calculated according to the following formula: MELD scores are reported as whole numbers, so the result of the equation above is rounded. UNOS has made the following modifications to the score:
If the patient has been dialyzed twice within the last 7 days, then the value for serum creatinine used should be 4.0 mg/dL
Any value less than one is given a value of 1 to prevent subtraction from any of the three factors, since the natural logarithm of a positive number below 1 yields a negative value.
The etiology of liver disease was subsequently removed from the model because it posed difficulties such as how to categorize patients with multiple causes of liver disease. Modification of the MELD score by excluding etiology of liver disease did not significantly affect the model's accuracy in predicting three-month survival. Patients with a diagnosis of liver cancer will be assigned a MELD score based on how advanced the cancer is.
Interpretation
In interpreting the MELD Score in hospitalized patients, the 3 month observed mortality is:
40 or more — 71.3% observed mortality
30–39 — 52.6% observed mortality
20–29 — 19.6% observed mortality
10–19 — 6.0% observed mortality
<9 — 1.9% observed mortality
Applications of MELD score:
The best outcomes with TIPS occur among patients with a MELD score less than 14.
Patients with MELD scores greater than 24 who are reasonable liver transplant candidates are probably best served by foregoing TIPS placement.
History
MELD was originally developed at the Mayo Clinic by Dr. Patrick Kamath, and at that point was called the "Mayo End-stage Liver Disease" score. It was derived in a series of patients undergoing TIPS procedures. The original version also included a variable based on the underlying etiology of the liver disease. The score turned out to be predictive of prognosis in chronic liver disease in general, and–with some modifications–came to be applied as an objective tool in assigning need for a liver transplant. The etiology turned out to be relatively unimportant, and was also regarded as relatively subjective; it was therefore removed from the score. MELD-Plus, a new score resulted from a collaboration between Massachusetts General Hospital and IBM was introduced in 2017.
proposed that MELD-Na score may better rank candidates based on their risk of pre-transplant mortality and is projected to save 50-60 lives total per year. Furthermore, a study published in the New England Journal of Medicine in 2008, estimated that using MELD-Na instead of MELD would save 90 lives for the period from 2005 to 2006. In his viewpoint published in June 2018, co-creator of MELD-Plus, Uri Kartoun, suggested that "...MELD-Plus, if incorporated into hospital systems, could save hundreds of patients every year in the United States alone."
